Research on long-term follow-up in individuals who have recovered from coronavirus disease-19 (COVID-19) would yield insights regarding their immunity status and identify those who need booster vaccinations. This study evaluated the longevity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific cellular and humoral memory responses, as well as T cell effector functionalities, at 1-2 months ( = 40), 8-9 months ( = 40), and 12 months/1 year ( = 27) following recovery from SARS-CoV-2 infection. CTL response by enzyme-linked immunospot (ELISPOT); levels of cytokine by Bio-Plex, natural killer (NK), CD4+ helper, and CD8+ cytotoxic T cell functionalities using flow cytometry; anti-SARS-CoV-2 IgG by ELISA; and levels of neutralizing antibodies (NAbs) by surrogate virus NAb assay were assessed. The levels of SARS-CoV-2-specific IgG and NAb at 1-2 and 8-9 months postrecovery were hand in hand and appeared declining. SARS-CoV-2-specific B, memory B and plasma cells, and T cells sustained up to 8-9 months. Increased expression of CD107a/IFN-γ by NK cells and cytotoxic T cells at 8-9 months could be indicative of SARS-CoV-2-specific effector functions. Recovered individuals with positive and negative IgG antibody status displayed T cell response up to 1 year and 8-9 months, respectively, emphasizing the durabilty of effector immunity up to 8-9 months regardless of IgG antibody status. Overall, the recovered individuals exhibited robust immunological memory, sustained T cell response with effector functionality against SARS-CoV-2 that persists for at least 8-9 months.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11832264PMC
http://dx.doi.org/10.1155/jimr/9743866DOI Listing

Publication Analysis

Top Keywords

8-9 months
32
cell response
12
months
9
immunological memory
8
8-9
8
months postrecovery
8
months  = 40
8
recovered individuals
8
igg antibody
8
antibody status
8

Similar Publications

Recurrent ischemic priapism is a common complication of sickle cell anemia (SCA) and is associated with devastating physical and psychosocial consequences. All previous trials for priapism prevention have failed to demonstrate clear efficacy. We conducted a randomized, controlled, double-blind phase 2 feasibility trial comparing fixed moderate-dose hydroxyurea plus placebo (usual care arm) versus fixed moderate-dose hydroxyurea plus tadalafil (experimental arm) in 64 men (18- 40 years) with at least three episodes of SCA-related priapism in the past 12 months.

View Article and Find Full Text PDF

Context: Noninvasive measurement of bone marrow adipose tissue using magnetic resonance imaging and proton density fat fraction (PDFF) may enhance clinical fractures prediction in postmenopausal women.

Objective: This study aimed to assess the association between PDFF measurements and clinical fracture incidence.

Methods: A longitudinal study was conducted.

View Article and Find Full Text PDF

Cancer of unknown primary (CUP) is a diagnosis that the primary lesion cannot be confirmed by a series of imaging, endoscopic and pathological examinations. The present study aimed to assess the clinical characteristics and survival outcomes of patients with CUP. The present retrospective observational study included patients diagnosed with malignancies confirmed as CUP using histopathology at the Oncology Department of the Fourth Hospital of Hebei Medical University (Shijiazhuang, China) from January 2009 to January 2021.

View Article and Find Full Text PDF

Objective: The aim of this his study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals.

Methods: Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015 to March 2024). Adults with moderate-to-severe psoriasis who initiated secukinumab treatment were identified and followed-up until March 2024, or disenrollment.

View Article and Find Full Text PDF

The Quit Together couples-focused pilot randomized trial of tobacco cessation for pregnant smokers.

Eur J Obstet Gynecol Reprod Biol

March 2025

Department of Obstetrics, Gynecology and Reproductive Biology, College of Human Medicine, Michigan State University, MI, USA; Center for Health Policy and Public Health, College of Political, Administrative and Communication Sciences, Babeș-Bolyai University, Cluj-Napoca, Romania; Department of Public Health, College of Political, Administrative and Communication Sciences, Babeș-Bolyai University, Cluj-Napoca, Romania.

Aims: This study reports on the feasibility and preliminary efficacy of prenatal and postnatal couples-focused telephone counseling for pregnant tobacco smokers.

Design And Setting: This pilot randomized controlled trial (RCT) was conducted online in Romania and enrolled a total of 90 pregnant smokers and 77 of their life partners.

Participants: 90 adult pregnant smokers and 77 of their life partners were randomized either to (1) Motivation and Problem Solving (MAPS) telephone counseling (n = 45 pregnant smokers who received up to 8 pre/postnatal telephone counseling sessions and n = 40 partners who received up to 4 sessions) or (2) usual care (n = 45 pregnant smokers and n = 37 partners).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!